Managing Partner, previous Chair of Osborne Clarke’s International Council, and co-founder of Osborne Clarke Spain, Núria specialises in corporate law and governance for multinational and listed companies.
Núria has over 30 years' experience in both transactional and advisory work, including IPOs and the regulatory aspects of listed companies – M&A, joint ventures, flotations, and environmental, social and governance (ESG).
Núria is a committee member and/or member of the board of directors for several investment fund management companies listed on the MAB, and IBEX 35-listed company Grifols, providing not only day-to-day corporate and regulatory advice, but leading big acquisitions projects and coordinating legal councils around the world. She has also participated in real estate projects, advising developers and retailers.
Her proactive approach marks Núria as an innovative problem solver, expertly staying ahead of the market to better anticipate the needs of her clients. Accordingly, she has been recognised by an eminent legal magazine as one of the ‘Top 50 inspiring women lawyers in Spain and Portugal’ for two years running.
Having been educated at the University of Barcelona, Núria graduated with a law degree in 1982 before completing a postgraduate degree in taxation. She is a member of the Barcelona Bar Association, the International Bar Association, and the International Fiscal Association.
Helping you succeed in tomorrow's world
“For me, my work should always be about making things happen. It should be about contributing to the business growth of my clients, and consequently, the economic and social growth of their regions. It’s so rewarding to know that my clients consider me a part of their business.
I'm also proud to be the Chairperson of the Probitas Foundation, championing the improvement of the medical and nutritional care being offered to marginalised areas of Spain and vulnerable communities in Africa.”
Advised global healthcare leader Grifols on the agreement with the Hong Kong’s Tiancheng International Investment Ltd. to acquire 100% of the shares of Tiancheng Pharmaceutical Holdings AG, which holds approximately a stake of 89.88% of Biotest ordinary shares and 1.08% of Biotest preferred shares for approximately EUR1.1bn. Read more >
Large acquisitions projects and co-ordination of day-to-day legal advice on all Grifols' subsidiaries worldwide.
$1.675 bn acquisition of the Novartis Transfusion Diagnostics Division.
$4 bn acquisition of US listed company Talecris Biotherapeutics.